IL17A and Patent ductus arteriosus: Moreover, both IL-27R deletion and iNOS inhibition were protective against PDA and, similar to DC depletion, reduced CD4+ T-cell expression of CD39, IL-17A, IL-17F, and RORγ in vivo (Figs. 5i–k).